Healthcare distributor Cencora (NYSE: COR) will be announcing earnings results this Wednesday before market open. Here’s what to expect.
Cencora met analysts’ revenue expectations last quarter, reporting revenues of $75.45 billion, up 10.3% year on year. It was a mixed quarter for the company, with a decent beat of analysts’ EPS estimates.
Is Cencora a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Cencora’s revenue to grow 7.5% year on year to $79.82 billion, slowing from the 10.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $3.83 per share.
Heading into earnings, analysts covering the company have grown increasingly bullish with revenue estimates seeing 4 upward revisions over the last 30 days (we track 12 analysts). Cencora has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Cencora’s peers in the health insurance providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. CVS Health delivered year-on-year revenue growth of 8.4%, beating analysts’ expectations by 5.1%, and Alignment Healthcare reported revenues up 49%, topping estimates by 5.7%. CVS Health’s stock price was unchanged after the resultswhile Alignment Healthcare was up 5.7%.
Read our full analysis of CVS Health’s results here and Alignment Healthcare’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Cencora is down 2.9% during the same time and is heading into earnings with an average analyst price target of $329.07 (compared to the current share price of $293.64).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
